# Spain warns of menopause drug shortage extension

2 October 2026 at 20:30

> The Aemps alerts that Lenzetto and Evopad supply issues could persist past November 2026 due to manufacturing problems and high demand.

The [Spanish Agency for Medicines and Health Products](<https://spainnews.co.uk/entity/spanish-agency-of-medicines-and-medical-devices-q8191326>) (Aemps) warns that the shortage of **Lenzetto**, a menopause symptom spray, could extend beyond November 2026. Manufacturer [Gedeon Richter](<https://spainnews.co.uk/entity/gedeon-richter-company-q630125>) cited device issues and high demand affecting multiple European nations.

Bexat Farmacéutica has ceased marketing Estradot patches, while **Evopad**, the only state-funded alternative, faces shortages until November 2026. Although Estraderm supply remains stable, Oestraclin Gel is currently excluded from National Health System funding.

Aemps has escalated these supply incidents to the [European Medicines Agency](<https://spainnews.co.uk/entity/european-medicines-agency-q130146>) to coordinate a response. Currently, no pharmaceutical companies have formalised requests for state funding for Lenzetto alternatives, impacting hormone treatment access across Spain.


#Lenzetto #Aemps #Menopause #HormoneReplacementTherapy #SpainHealth

## Related news

## [Catalonia to allow pharmacy-made menopause drugs](<https://spainnews.co.uk/article/catalonia-to-allow-pharmacy-made-menopause-drugs-dfff4e1e>)

30 September 2026 at 13:47